Home Tools
Log in
Cart

BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T12311 Tirabrutinib hydrochloride 1439901-97-9 98.90%
Tirabrutinib hydrochloride
Tirabrutinib hydrochloride (GS-4059 (hydrochloride)) is a selective and novelBTK with IC50 2.2 nm inhibitor.
T38960L QL-X-138 HCl 98.89%
QL-X-138 HCl
QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK....
T9072 Tuxobertinib 2414572-47-5 98.86%
Tuxobertinib
Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK a...
TQ0242 Fenebrutinib 1434048-34-6 98.84%
Fenebrutinib
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
T10626 (Rac)-IBT6A 1412418-47-3 98.68%
(Rac)-IBT6A
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T10870L CP-547632 252003-65-9 98.51%
CP-547632
CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is ...
T73334 Larotinib 1438072-11-7 98.45%
Larotinib
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
T38960 QL-X-138 1469988-63-3 98.41%
QL-X-138
QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, ...
T2472 CGI-1746 910232-84-7 98.27%
CGI-1746
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
TQ0039 (±)-Zanubrutinib 1633350-06-7 98.19%
(±)-Zanubrutinib
(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achiev...
T73463 NX-2127 2416131-46-7 98.11%
NX-2127
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activ...
T64124 Sunvozertinib 2370013-12-8 98.11%
Sunvozertinib
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inh...
T9192 BIIB068 1798787-27-5 98.05%
BIIB068
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
T13447 (R)-Zanubrutinib 1691249-44-1 98.04%
(R)-Zanubrutinib
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
T4387 Evobrutinib 1415823-73-2 98.04%
evobrutinib
Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the deve...
T6078 Saracatinib 379231-04-6 98.03%
Saracatinib
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T12542 Rilzabrutinib 1575596-29-0 97.87%
Rilzabrutinib
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T2603 Spebrutinib 1202757-89-8 97.14%
Spebrutinib
Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity...
T13564 AZ7550 1421373-99-0 97.07%
AZ7550
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
T16157 MT-802 2231744-29-7 97%
MT-802
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
Tirabrutinib hydrochloride
T12311
Tirabrutinib hydrochloride (GS-4059 (hydrochloride)) is a selective and novelBTK with IC50 2.2 nm inhibitor.
QL-X-138 HCl
T38960L
QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK....
Tuxobertinib
T9072
Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK a...
Fenebrutinib
TQ0242
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
(Rac)-IBT6A
T10626
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
CP-547632
T10870L
CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is ...
Larotinib
T73334
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
QL-X-138
T38960
QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, ...
CGI-1746
T2472
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
(±)-Zanubrutinib
TQ0039
(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achiev...
NX-2127
T73463
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activ...
Sunvozertinib
T64124
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inh...
BIIB068
T9192
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
(R)-Zanubrutinib
T13447
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
evobrutinib
T4387
Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the deve...
Saracatinib
T6078
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
Rilzabrutinib
T12542
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
Spebrutinib
T2603
Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity...
AZ7550
T13564
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
MT-802
T16157
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
1 2 3 4
TargetMol